Top Journals Based on Impact Factor
College of Pharmacy Faculty Research Profiles
Michigan Experts is an expertise portal that promotes interdisciplinary clinical & translational research.
Open Researcher and Contributor ID (ORCID)
ORCID is an open, non-profit, community-based effort to create & maintain a registry of unique research identifiers. Using a transparent method of linking research activities & outputs to these identifiers, that supports automated linkages between you & your professional activities helps ensure that your work is recognized.
Welcome to the research guide for the College of Pharmacy. Tabs on the top of this page comprise the best sources for finding journal articles, drug information, & point of care resources.
If you've been searching & can't find what you're looking for, feel free to give me a call! I can:
- Help with your literature searches
- Provide one-on-one advice about your research topic
- Teach you advanced techniques for database searching
- Assist you to set up auto alerts for selected search strategies & TOC updates
- Orient you to the array of library resources available through UM
- Teach you about citation management tools, such as EndNote or Refworks, that can save you time when collecting citations & formatting your citations & bibliographies
Natural Medicines combines Natural Standard & Natural Medicines Comprehensive Database. Provides up-to-date clinical data on the natural medicines, herbal medicines, and dietary supplements. Includes links ro Interaction & Effectiveness Checkers, & information on nutrient depletion, pregnancy & lactation, & adverse effects, right on the front page.
New Cures Require New Pricing Policies
One critical incentive for ongoing drug discovery and development is the temporary monopoly pricing that manufacturers can command for novel drugs. Yet this incentive, embedded in current patent and regulatory policy, does not guarantee that manufacturers will deliver novel products with clinically meaningful benefits. Indeed there are many diseases—including Alzheimer’s disease and Amyotrophic lateral sclerosis (ALS)—that pose significant patient, family, and societal burden but have not benefited from meaningful treatment advances.